As one of the latest efforts to stir the stagnated migraine market - Pozen Inc.'s combination therapy Trexima, which pairs sumatriptan with the non-steroidal anti-inflammatory drug naproxen - continues to have trouble, Endo Pharmaceuticals Inc.'s Frova (frovatriptan) might be able to make headway. But it's too early to put a lot of money on that bet. (BioWorld Financial Watch) Read More
